- Innocan (INNO) is launching its licensing and commercialization strategy work for cannabinoid (CBD) therapy in the veterinary field
- The company views the veterinary market as an important sector which can benefit from the potential therapeutic effects of CBD
- Innocan is a pharmaceutical tech company that operates under Pharmaceuticals and Consumer Wellness segments
- InnoCan Pharma Corporation (INNO) is down 4.17 per cent, trading at C$0.23 per share at 12:37 pm ET
Innocan (INNO) is launching its licensing and commercialization strategy work for cannabinoid (CBD) therapy in the veterinary field.
The company reports that CBD has shown to have a wide range of therapeutic properties, including anti-inflammatory, analgesic, and anti-anxiety effects. It views the veterinary market as an important sector which can benefit from the potential therapeutic effects of CBD.
Iris Bincovich, CEO of Innocan, commented on the news.
“We are excited to announce the appointment of a dedicated internal team covering the financial, scientific, and legal aspects. These are required to engage with prospective clients in the veterinary field. Our goal is to commercialize, partner, and/or sell Innocan’s intellectual property portfolio to veterinary indications. We believe there is significant potential in the veterinary market for our CBD-based products.”
The company said that the appointment of a dedicated internal team will foster engagement between Innocan and prospective clients in the veterinary field. It allows it to explore potential collaborations and commercialization opportunities.
Innocan reported that its innovative CBD-based products have previously demonstrated promise in human clinical trials. The company is now eager to explore the potential for these products in the veterinary field.
About Innocan
Innocan is a pharmaceutical tech company that operates under Pharmaceuticals and Consumer Wellness segments. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies. These comprises of cannabinoids science, to treat various conditions to improve patients’ quality of life.
In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.
InnoCan Pharma Corporation (INNO) is down 4.17 per cent, trading at C$0.23 per share at 12:37 pm ET.